Author

I. Garner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:differential expression· 2

Frequent Co-Authors

R. Brown· 4 shared I. McNeish· 2 shared J. Robinson· 2 shared P. Spiliopoulou· 2 shared S. Spear· 2 shared D. Ennis· 1 shared D. J. Murphy· 1 shared E. Curry· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

R. Brown

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer

J. Robinson, G. Flint, I. Garner, S. Galli, T. Maher, M. Kuimova, R. Vilar, I. McNeish, R. Brown, H. C. Keun, M. Di Antonio

This study identifies G-quadruplex structures as regulators of long-range transcriptional reprogramming in drug-resistant ovarian cancer, showing their role in promoting resistance and potential as therapeutic targets.

bioRxiv · Jun 24, 2024 · PreprintCancer Biology

cMYC-mediated immune repression is reversed by inhibition of H3K9/H3K27 methylation maintenance

I. Dye, S. Laing, I. Garner, H. B. Mirza, N. Iyer, N. Brady, P. Spiliopoulou, S. Spear, J. Robinson, F. Fiorentino, M. J. Fuchter, D. J. Murphy, I. J. McNeish, R. Brown

This study shows that inhibiting H3K27/H3K9 methylation maintenance reverses cMYC-mediated immune repression in cancer, improving survival in mouse models.

bioRxiv · Oct 18, 2023 · PreprintCancer Biology

Dual G9A and EZH2 inhibition stimulates an anti-tumour immune response in ovarian high-grade serous carcinoma

P. Spiliopoulou, S. Spear, H. Mirza, I. Garner, L. Mcgarry, F. Grundland-Freile, Z. Cheng, D. Ennis, S. McNamara, M. Natoli, S. Mason, K. Blyth, P. Adams, P. Roxburgh, M. Fuchter, , I. McNeish

This study shows that dual inhibition of G9A and EZH2 in ovarian cancer enhances anti-tumour immune responses by altering the immune microenvironment and reducing tumour growth.

bioRxiv · May 9, 2021Cancer Biology

Chromatin accessibility changes at intergenic regions associates with ovarian cancer drug resistance

J. Gallon, E. Loomis, E. Curry, N. Martin, L. Brody, I. Garner, R. Brown, J. M. Flanagan

The paper examines chromatin accessibility changes in ovarian cancer cell lines resistant to platinum-based chemotherapy, finding intergenic region alterations linked to drug resistance and Pt-adduct distribution.

bioRxiv · Feb 24, 2021Cancer Biology